CBR3 and gastric cancer: Despite the promising diagnostic potential of CBR3-AS1 and PCA3 in GC, the current study has some limitations, including its single-center cohort, lack of functional validation assays (such as gene knockdown/overexpression, RNA-sequencing, and pathway analysis).